Rafal Swierzewski, PhD Cancer Survivor; Associate Consultant, European Cancer Patient Coalition (ECPC), Brussels, Belgium; Expert, European Medicines Agency (EMA), London, Great Britain; Co-founder and CEO, Foundation for Patients with Rare Diseases “COCARDA,” Lodz,...
For several years, the American Society of Clinical Oncology (ASCO) has offered authors of research funded by academic institutions, not-for-profit organizations, philanthropic foundations, and government agencies an open access publishing option in its journals....
Carolyn Hustad, PhD, Merck & Co., Inc., Kenilworth, NJ In the last five years, an increasing number of pharmaceutical and biotech companies have joined forces to develop and commercialize new compounds or drug combinations rather than go it alone. This trend is...
Molly E. Hoke, PhD, ISMPP CMPP™ Data transparency is a frequently mentioned and is a passionately discussed topic of relevance to, and has implications for, any publications professional working today in the world of clinical trial data generation and dissemination....
Susan C. Scott, Scott Pharma Solutions Ltd, Ashwell, UK While there are many factors, such as author selection, full disclosure and acknowledgement, and data access, that are common to planning any publication,1,2 different issues arise when managing a publication...
Beatrix Doerr, DVM, PhD, Coriuvar Consulting; Gillian Pritchard, MSc, MRCP, MFPM, MBA, Sylexis Ltd The medical device industry is similar, and yet different, to the pharmaceutical industry with regards to medical writing. While publications and presentations follow...
